{"id":"lovaza-omega-3-acid-ethyl-esters","safety":{"commonSideEffects":[{"rate":"~26%","effect":"Eructation (fish-flavored burps)"},{"rate":"~9%","effect":"Dyspepsia"},{"rate":"~7%","effect":"Nausea"},{"rate":null,"effect":"Increased bleeding tendency"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Omega-3 polyunsaturated fatty acids (EPA and DHA) work by inhibiting acyl-CoA synthetase and reducing the availability of precursors for triglyceride synthesis in the liver, while also enhancing the clearance of triglyceride-rich lipoproteins. This results in significant reductions in serum triglyceride concentrations, particularly in patients with severe hypertriglyceridemia.","oneSentence":"LOVAZA reduces triglyceride levels by providing omega-3 fatty acids (EPA and DHA) that decrease hepatic triglyceride synthesis and increase triglyceride clearance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:16.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypertriglyceridemia (≥500 mg/dL) as an adjunct to diet"}]},"trialDetails":[{"nctId":"NCT06195306","phase":"PHASE2","title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-28","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":66},{"nctId":"NCT03598309","phase":"PHASE2","title":"Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-05","conditions":"Lung Diseases, Lung Cancer, Protection Against","enrollment":19},{"nctId":"NCT00678743","phase":"PHASE4","title":"An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2007-08","conditions":"Dyslipidemias","enrollment":17},{"nctId":"NCT00135226","phase":"PHASE4","title":"ASCEND: A Study of Cardiovascular Events iN Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2005-03","conditions":"Diabetes Mellitus","enrollment":15480},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03175666","phase":"PHASE1, PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03167177","phase":"PHASE1, PHASE2","title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03169738","phase":"PHASE1, PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03197584","phase":"PHASE1, PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03197571","phase":"PHASE1, PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03167164","phase":"PHASE1, PHASE2","title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT05281562","phase":"PHASE2, PHASE3","title":"Immunonutrition for Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Prisma Health-Midlands","startDate":"2023-02-08","conditions":"Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer","enrollment":1},{"nctId":"NCT03329248","phase":"PHASE1, PHASE2","title":"QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-11-06","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT01034540","phase":"NA","title":"Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2010-03","conditions":"Hypertriglyceridemia","enrollment":23},{"nctId":"NCT03387098","phase":"PHASE1, PHASE2","title":"QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-12-28","conditions":"Pancreatic Cancer","enrollment":4},{"nctId":"NCT04268134","phase":"PHASE2","title":"Altering Lipids for Tolerance of Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-07-28","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT03831698","phase":"PHASE2","title":"Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2019-02-06","conditions":"Colorectal Cancer, Lynch Syndrome","enrollment":21},{"nctId":"NCT03443076","phase":"NA","title":"Bioavailability of EPA + DHA in a SMEDS Formulation","status":"COMPLETED","sponsor":"Midwest Center for Metabolic and Cardiovascular Research","startDate":"2018-02-16","conditions":"Bioavailability","enrollment":24},{"nctId":"NCT00915902","phase":"PHASE2, PHASE3","title":"Fish Oil Study for High Triglyceride Levels in Children","status":"COMPLETED","sponsor":"Babu Balagopal","startDate":"2009-07","conditions":"Hypertriglyceridemia","enrollment":42},{"nctId":"NCT04308889","phase":"EARLY_PHASE1","title":"Pro-Resolving Mediators in Acute Inflammation in Humans","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-07-02","conditions":"Inflammation; Skin, Resolution, Blister","enrollment":19},{"nctId":"NCT02113163","phase":"PHASE1","title":"PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA","status":"COMPLETED","sponsor":"Thetis Pharmaceuticals LLC","startDate":"2014-03","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia","enrollment":32},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT04177680","phase":"PHASE2","title":"Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2020-06-03","conditions":"Hypertriglyceridemia","enrollment":100},{"nctId":"NCT02285166","phase":"","title":"Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-10-21","conditions":"Hyperlipidemia","enrollment":15330},{"nctId":"NCT00286234","phase":"PHASE4","title":"Niacin, N-3 Fatty Acids and Insulin Resistance","status":"COMPLETED","sponsor":"University of South Dakota","startDate":"2007-10","conditions":"Metabolic Syndrome, Hypertriglyceridemia","enrollment":68},{"nctId":"NCT04521465","phase":"","title":"Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-11-09","conditions":"Evaporative Dry Eye Disease","enrollment":36},{"nctId":"NCT04756180","phase":"PHASE3","title":"An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.","status":"COMPLETED","sponsor":"Abbott","startDate":"2016-10","conditions":"Hypertriglyceridemia","enrollment":248},{"nctId":"NCT03415152","phase":"","title":"A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy","status":"COMPLETED","sponsor":"Abbott","startDate":"2018-01-24","conditions":"History of Myocardial Infarction, Hypertriglyceridemia","enrollment":3000},{"nctId":"NCT01823991","phase":"EARLY_PHASE1","title":"COGNUTRIN in Breast Cancer Survivors","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-07-30","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT01041521","phase":"PHASE4","title":"The Impact of Omega Three Fatty Acids on Vascular Function in HIV","status":"COMPLETED","sponsor":"Tufts University","startDate":"2010-01","conditions":"High Triglyceride Level, HIV Infection","enrollment":129},{"nctId":"NCT00795717","phase":"PHASE4","title":"Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial","status":"COMPLETED","sponsor":"Tufts University","startDate":"2008-07","conditions":"Cardiovascular Disease, HIV Infection","enrollment":41},{"nctId":"NCT02153073","phase":"","title":"Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-05-29","conditions":"Hyperlipidemia","enrollment":3084},{"nctId":"NCT02824432","phase":"PHASE4","title":"Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-04","conditions":"Hyperlipidemia","enrollment":37},{"nctId":"NCT00454493","phase":"NA","title":"The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"Olive View-UCLA Education & Research Institute","startDate":"2006-08","conditions":"Coronary Artery Disease","enrollment":71},{"nctId":"NCT02839902","phase":"PHASE4","title":"Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-12-27","conditions":"Hyperlipidemia","enrollment":53},{"nctId":"NCT00446966","phase":"PHASE4","title":"Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"Chirag Sandesara","startDate":"2007-02","conditions":"Atrial Fibrillation","enrollment":260},{"nctId":"NCT00577590","phase":"NA","title":"Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2003-10","conditions":"Diabetes Mellitus, Type II","enrollment":78},{"nctId":"NCT01712867","phase":"NA","title":"The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels","status":"COMPLETED","sponsor":"Enzymotec","startDate":"2012-10","conditions":"Patients With Hypertriglyceridemia","enrollment":201},{"nctId":"NCT00504309","phase":"NA","title":"Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides","status":"COMPLETED","sponsor":"Penn State University","startDate":"2007-07","conditions":"Hypertriglyceridemia","enrollment":28},{"nctId":"NCT01107964","phase":"NA","title":"Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2010-07","conditions":"Dry Eye Syndrome","enrollment":27},{"nctId":"NCT00903409","phase":"PHASE3","title":"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-15","conditions":"Hypertriglyceridemia","enrollment":188},{"nctId":"NCT01624727","phase":"NA","title":"Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2009-06","conditions":"Coronary Heart Disease, Metabolic Syndrome","enrollment":338},{"nctId":"NCT00791089","phase":"PHASE4","title":"Effects of Fish Oil on Post Ablation Arrhythmias","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2008-11","conditions":"Atrial Fibrillation","enrollment":12},{"nctId":"NCT01002118","phase":"NA","title":"Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2008-01-25","conditions":"Cardiovascular Disease","enrollment":1},{"nctId":"NCT01191177","phase":"PHASE1, PHASE2","title":"Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease","status":"WITHDRAWN","sponsor":"Boston Children's Hospital","startDate":"2011-01","conditions":"Liver Disease, Short Bowel Syndrome","enrollment":""},{"nctId":"NCT01784042","phase":"EARLY_PHASE1","title":"Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-03","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00246701","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-01","conditions":"Hypertriglyceridemia","enrollment":256},{"nctId":"NCT00815685","phase":"NA","title":"A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-07","conditions":"Cancer Cachexia","enrollment":36},{"nctId":"NCT01894581","phase":"NA","title":"Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-07","conditions":"Obesity, Fertility","enrollment":39},{"nctId":"NCT00435045","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Hypertriglyceridemia","enrollment":245},{"nctId":"NCT00402363","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11","conditions":"Fibrillation, Atrial","enrollment":663},{"nctId":"NCT02370537","phase":"PHASE2","title":"A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency","enrollment":490},{"nctId":"NCT00828178","phase":"PHASE4","title":"Efficacy of Fish Oil in Lupus Patients","status":"COMPLETED","sponsor":"Michelle Petri M.D.,MPH","startDate":"2009-02","conditions":"Systemic Lupus Erythematosus","enrollment":106},{"nctId":"NCT01350973","phase":"PHASE3","title":"Efficacy of TAK-085 in Participants With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Hypertriglyceridemia","enrollment":611},{"nctId":"NCT01350999","phase":"PHASE3","title":"Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Hypertriglyceridemia","enrollment":503},{"nctId":"NCT00944229","phase":"PHASE3","title":"The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure","status":"TERMINATED","sponsor":"Columbia University","startDate":"2010-01","conditions":"Heart Failure","enrollment":58},{"nctId":"NCT01180764","phase":"PHASE4","title":"Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2010-08","conditions":"Hypertriglyceridemia","enrollment":""},{"nctId":"NCT00694746","phase":"PHASE1","title":"Study of Fish Oil to Reduce ALT Levels in Adolescents","status":"TERMINATED","sponsor":"Boston University","startDate":"2008-06","conditions":"Non-alcoholic Fatty Liver Disease, Fatty Liver","enrollment":3},{"nctId":"NCT02625870","phase":"PHASE3","title":"Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-12","conditions":"Hypertriglyceridemia","enrollment":240},{"nctId":"NCT02155816","phase":"NA","title":"Omega 7 + 3 Combination and Systemic Inflammation","status":"COMPLETED","sponsor":"Appalachian State University","startDate":"2014-05","conditions":"Inflammation","enrollment":68},{"nctId":"NCT01208961","phase":"PHASE2","title":"Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Severe Hypertriglyceridemia","enrollment":54},{"nctId":"NCT01431690","phase":"PHASE1","title":"Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Hypertriglyceridemia","enrollment":52},{"nctId":"NCT00935766","phase":"PHASE3","title":"Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries","status":"TERMINATED","sponsor":"Denver Health and Hospital Authority","startDate":"2009-09","conditions":"Metabolic Diseases, Endocrine System Diseases, Heart Disease","enrollment":76},{"nctId":"NCT01725646","phase":"PHASE3","title":"An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients","status":"COMPLETED","sponsor":"Excelsior","startDate":"2011-07","conditions":"Hypertriglyceridemia","enrollment":253},{"nctId":"NCT00845845","phase":"PHASE2","title":"Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2006-03","conditions":"Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis","enrollment":12},{"nctId":"NCT00069784","phase":"PHASE3","title":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":12537},{"nctId":"NCT00805870","phase":"PHASE2","title":"The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers","status":"COMPLETED","sponsor":"Western Michigan University","startDate":"2009-03","conditions":"Muscle Damage, Muscle Inflammation","enrollment":20},{"nctId":"NCT00517972","phase":"PHASE2","title":"Omacor for Perimenopausal Depression","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"","conditions":"Depression","enrollment":""},{"nctId":"NCT01216982","phase":"PHASE2","title":"Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders","status":"UNKNOWN","sponsor":"United States Department of Defense","startDate":"2010-11","conditions":"Mood Disorders, Depression, Combat Disorders","enrollment":256},{"nctId":"NCT00891293","phase":"PHASE4","title":"A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Hypertriglyceridemia","enrollment":93},{"nctId":"NCT00246636","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Hypertriglyceridemia","enrollment":167},{"nctId":"NCT00934219","phase":"PHASE4","title":"Triglyceride Lowering Study","status":"UNKNOWN","sponsor":"Jewish Hospital, Cincinnati, Ohio","startDate":"2009-07","conditions":"Hypertriglyceridemia","enrollment":25},{"nctId":"NCT00251134","phase":"PHASE3","title":"OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction","status":"COMPLETED","sponsor":"Stiftung Institut fuer Herzinfarktforschung","startDate":"2003-10","conditions":"Myocardial Infarction","enrollment":3800},{"nctId":"NCT00688961","phase":"EARLY_PHASE1","title":"Effects of Omacor and Aspirin on Platelet Function","status":"COMPLETED","sponsor":"Sanford Research","startDate":"2007-06","conditions":"Healthy","enrollment":10},{"nctId":"NCT00487591","phase":"","title":"An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2006-11","conditions":"Mixed Dyslipidemia","enrollment":40},{"nctId":"NCT00257283","phase":"PHASE4","title":"Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis","status":"COMPLETED","sponsor":"Pronova BioPharma","startDate":"2002-11","conditions":"Kidney Failure, Chronic","enrollment":200},{"nctId":"NCT00296153","phase":"PHASE4","title":"Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment","status":"COMPLETED","sponsor":"Pronova BioPharma","startDate":"2006-02","conditions":"Human Immunodeficiency Virus, Ischemic Heart Disease","enrollment":51},{"nctId":"NCT00294216","phase":"PHASE3","title":"Omacor and Placebo in Carotid Plaque Stability","status":"COMPLETED","sponsor":"Pronova BioPharma","startDate":"2003-08","conditions":"Cardiovascular Disease","enrollment":121}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"HEADACHE"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"TREMOR"},{"count":1,"reaction":"ANXIETY"},{"count":1,"reaction":"APPLICATION SITE DERMATITIS"},{"count":1,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":1,"reaction":"APPLICATION SITE PAIN"},{"count":1,"reaction":"APPLICATION SITE PRURITUS"}],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fish Oil","Lovaza"],"phase":"marketed","status":"active","brandName":"LOVAZA Omega 3-acid ethyl esters","genericName":"LOVAZA Omega 3-acid ethyl esters","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LOVAZA reduces triglyceride levels by providing omega-3 fatty acids (EPA and DHA) that decrease hepatic triglyceride synthesis and increase triglyceride clearance. Used for Severe hypertriglyceridemia (≥500 mg/dL) as an adjunct to diet.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}